An Effective Treatment for Coronavirus (COVID-19)
et al., Mar 2020
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Discussion of existing research, treatment guidelines, and mechanisms of action for CQ and HCQ, recommending use.
1.
Mothae et al., SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis, Virology, doi:10.1016/j.virol.2025.110607.
2.
Monsalve et al., NETosis: A key player in autoimmunity, COVID-19, and long COVID, Journal of Translational Autoimmunity, doi:10.1016/j.jtauto.2025.100280.
3.
Xie et al., The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death, Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6.
4.
Gkioulekas et al., Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2, Tasman Medical Journal, 6:4, tasmanmedicaljournal.com/2024/10/use-of-hydroxychloroquine-in-multidrug-protocols-for-sars-cov-2a/.
5.
Gortler et al., Those Published “17,000 Hydroxychloroquine Deaths” Never Happened, Brownstone Journal, brownstone.org/articles/those-published-17000-hydroxychloroquine-deaths-never-happened/.
6.
Boretti et al., Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection, Coronaviruses, doi:10.2174/0126667975327612240902104505.
7.
Gortler (B) et al., Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America, Brownstone Journal, brownstone.org/articles/trumps-63-million-doses-of-hydroxychloroquine-could-have-been-great-for-america/.
8.
Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.
9.
Asaba et al., Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections, Journal of Inflammation Research, doi:10.2147/jir.s474707.
10.
Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.
11.
Ali et al., SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication, Journal of Clinical Medicine, doi:10.3390/jcm12186079.
12.
Brouqui et al., There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view, New Microbes and New Infections, doi:10.1016/j.nmni.2023.101155.
13.
Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.
14.
Boretti (B), A., Pharmacotherapy for Covid-19 infection in the countries of the Cooperation Council for the Arab States, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2021.08.005.
15.
Vigbedor et al., Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions, Journal of Applied Pharmaceutical Science, doi:10.7324/JAPS.2021.110825.
16.
Kaur et al., Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?, Medical Hypotheses, doi:10.1016/j.mehy.2021.110539.
17.
Raoult, D., Rational for meta-analysis and randomized treatment: the COVID-19 example, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.10.012.
18.
Matada et al., A comprehensive review on the biological interest of quinoline and its derivatives, Bioorganic & Medicinal Chemistry, doi:10.1016/j.bmc.2020.115973.
19.
IHU, Natural history and therapeutic options for COVID-19, Expert Review of Clinical Immunology, www.mediterranee-infection.com/wp-content/uploads/2020/09/ERM-2020-0073.R1_Proof_hi.pdf.
20.
Hecel et al., Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?, Pharmaceuticals, 13:9, 228, doi:10.3390/ph13090228.
21.
Li et al., Is hydroxychloroquine beneficial for COVID-19 patients?, Cell Death & Disease volume 11, doi:10.1038/s41419-020-2721-8.
22.
Goldstein, L., Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of Clinical Evidence and Expert Opinion from Physicians’ Surveys, Preprint, July 7, 2020, wattsupwiththat.com/2020/07/07/hydroxychloroquine-based-covid-19-treatment-a-systematic-review-of-clinical-evidence-and-expert-opinion-from-physicians-surveys/.
23.
Roussel et al., Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences, New Microbes and New Infections, Volume 38
, doi:10.1016/j.nmni.2020.100710.
24.
Mo et al., Chloroquine phosphate: therapeutic drug for COVID-19, Journal of Southern Medical University, doi:10.12122/j.issn.1673-4254.2020.04.22.
25.
Gao et al., Update on Use of Chloroquine/Hydroxychloroquine to Treat Coronavirus Disease 2019 (COVID-19), Biosci Trends, May 21, 2020, 14:2, 156-158, doi:10.5582/bst.2020.03072.
26.
Derwand et al., Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?, Medical Hypotheses, doi:10.1016/j.mehy.2020.109815.
27.
Sahraei et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine, International Journal of Antimicrobial Agents, April 2020, 55:4, doi:10.1016/j.ijantimicag.2020.105945.
28.
Todaro et al., An Effective Treatment for Coronavirus (COVID-19), github.com/covidtrial/info/raw/master/An%20Effective%20Treatment%20for%20Coronavirus%20(COVID-19).pdf.
Todaro et al., 13 Mar 2020, preprint, 2 authors.
An Effective Treatment for Coronavirus (COVID-19)
doi:10.1016/S1473-3099(03)00806-5.4
Recent guidelines from South Korea and China report that chloroquine is an effective antiviral therapeutic treatment against Coronavirus Disease 2019. Use of chloroquine (tablets) is showing favorable outcomes in humans infected with Coronavirus including faster time to recovery and shorter hospital stay. US CDC research shows that chloroquine also has strong potential as a prophylactic (preventative) measure against coronavirus in the lab, while we wait for a vaccine to be developed. Chloroquine is an inexpensive, globally available drug that has been in widespread human use since 1945 against malaria, autoimmune and various other conditions.
License Due to urgency, certain parts of this publication are taken directly from their attributed source. Cite them accordingly. In all other circumstances, the GNU General Public License v3.0 applies.
Disclaimer This white paper is for information purposes only. The authors and or its affiliates does not guarantee the accuracy of or the conclusions reached in this white paper, and this white paper is provided "as is". The authors and or its affiliates not make and expressly disclaims all representations and warranties, express, implied, statutory or otherwise, whatsoever, including, but not limited to: (i) warranties of merchantability, fitness for a particular purpose, suitability, usage, title or noninfringement; (ii) that the contents of this white paper are free from error; and (iii) that such contents will not infringe third-party rights. The authors and or its affiliates shall have no liability for damages of any kind arising out of the use, reference to, or reliance on this white paper or any of the content contained herein, even if advised of the possibility of such damages. In no event will the authors and or its affiliates be liable to any person or entity for any damages, losses, liabilities, costs or expenses of any kind, whether direct or indirect, consequential, compensatory, incidental, actual, exemplary, punitive or special for the use of, reference to, or reliance on this white paper or any of the content contained herein, including, without..
References
Kono, Tatsumi, Imai, Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK, J
Martínez, martinez-aceves@yale
Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, International Journal of Antimicrobial Agents Available online
Rodrigo, Luiza, Paula, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models, J
Zhang, Yi, Li, Chloroquine inhibits the endosomal Viral an RNA Release and autophagy in-dependent Viral Replication and Effectively Prevents CARE OF to Fetal Transmission of Zika Virus, J] Antiviral Res, doi:10.1016/j.antiviral.2019.104547